|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Alantos Pharmaceuticals Holdings Inc., of Cambridge, Mass., initiated a Phase I study of ALS 2-0426, an orally active, small-molecule inhibitor of dipeptidyl peptidase IV (DPP-IV), in Type II diabetes. The study, designed in two parts, will enroll about 50 healthy male volunteers to first test a single, ascending dose in sequential cohort design. That will be followed by a multiple dose study, also in healthy volunteers.
o Algeta ASA, of Oslo, Norway, entered a research collaboration to develop new targeted radiotherapeutics with Affibody AB, of Stockholm, Sweden. Specifically, the partners will combine Algeta's TH-1 technology for attaching the ...